Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study

European Journal of Cancer

Volumn 48, Issue 8, 2012, Pages 1126-1132

  Kabbinavar, Fairooz F ^a   Flynn, Patrick J ^b   Kozloff, Mark ^c   Ashby, Mark A ^d   Sing, Amy ^d   Barr, Charles E ^d   Grothey, Axel ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Minnesota Oncology and Hematology Professional Association   (United States)

^c Ingalls Memorial Hospital   (United States)

^d GENENTECH INC   (United States)

^e Mayo Clinic   (United States)

Author keywords

Antiangiogenesis; Biologics; GI perforation; Registry; Systemic therapy; Vascular endothelial growth factor inhibition

Indexed keywords

BEVACIZUMAB;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; FOLLOW UP; HUMAN; INCIDENCE; LONG TERM CARE; METASTASIS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COLORECTAL NEOPLASMS; HUMANS; INTESTINAL PERFORATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84860449805     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.02.052     Document Type: Article

References (27)

1. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
2. H.I. Hurwitz, L. Fehrenbacher, and J.D. Hainsworth Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 15 2005 3502 3508
3. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 12 2007 1539 1544
4. A. Grothey, M.M. Sugrue, and D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 33 2008 5326 5334
5. M. Kozloff, M.U. Yood, and J. Berlin Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study Oncologist 14 9 2009 862 870
6. National Cancer Institute. National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. Bethesda, MD: National Institutes of Health. NIH Publication No. 03-5410. Available at: < http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf >; 2006 [accessed 23.03.11].
7. F.A. Eskens, and J. Verweij The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review Eur J Cancer 42 18 2006 3127 3139
8. M.W. Saif, A. Elfiky, and R.R. Salem Gastrointestinal perforation due to bevacizumab in colorectal cancer Ann Surg Oncol 14 6 2007 1860 1869
9. H.M. Verheul, and H.M. Pinedo Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 7 6 2007 475 485
10. R.S. Herbst, V.J. O'Neill, and L. Fehrenbacher Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer J Clin Oncol 25 30 2007 4743 4750
11. R.M. Bukowski, F.F. Kabbinavar, and R.A. Figlin Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 29 2007 4536 4541
12. L. Kindler, R. Ansari, and E. Lester Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC) Proc Am Soc Clin Oncol 22 2003 259 [abstract 1037]
13. C.H. Crane, L.M. Ellis, and J.L. Abbruzzese Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer J Clin Oncol 24 7 2006 1145 1151
14. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2007 2666 2676
15. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 2007 5180 5186
16. S. Hapani, D. Chu, and S. Wu Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 6 2009 559 568
17. J.H. Heinzerling, and S. Huerta Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management Curr Surg 63 5 2006 334 337
18. M.W. Saif, A. Elfiky, and R.R. Salem Gastrointestinal perforation due to bevacizumab in colorectal cancer Ann Surg Oncol 14 6 2007 1860 1869
19. F. Lordick, H. Geinitz, J. Theisen, A. Sendler, and M. Sarbia Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases Int J Radiat Oncol Biol Phys 64 5 2006 1295 1298
20. L.E. McCahill, G.A. Yothers, and S. Sharif A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: results of NSABP C-10 J Clin Oncol 28 Suppl. 2010 267s [abstr 3527]
21. C.J. Allegra, G. Yothers, and M.J. O'Connell Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 20 2009 3385 3390
22. A. De Gramont, E. Van Cutsem, and J. Tabernero AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer J Clin Oncol 29 Suppl. 4 2011 362 [abstr]
23. E. Van Cutsem, F. Rivera, and S. Berry Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 11 2009 1842 1847
24. R.C. Kaplan, S.R. Heckbert, and T.D. Koepsell Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators J Am Geriatr Soc 49 2 2001 126 133
25. F.F. Kabbinavar, H.I. Hurwitz, J. Yi, S. Sarker, and O. Rosen Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials J Clin Oncol 27 2 2009 199 205
26. B.D. Badgwell, E.R. Camp, and B. Feig Management of bevacizumab- associated bowel perforation: a case series and review of the literature Ann Oncol 19 3 2008 577 582
27. A.L. Cohn, T. Bekaii-Saab, and J.C. Bendell Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP) J Clin Oncol 28 Suppl. 2010 284s [abstr 3596]